[go: up one dir, main page]

MX2020005472A - Sistemas de administración de fármacos a base de maitansinoide. - Google Patents

Sistemas de administración de fármacos a base de maitansinoide.

Info

Publication number
MX2020005472A
MX2020005472A MX2020005472A MX2020005472A MX2020005472A MX 2020005472 A MX2020005472 A MX 2020005472A MX 2020005472 A MX2020005472 A MX 2020005472A MX 2020005472 A MX2020005472 A MX 2020005472A MX 2020005472 A MX2020005472 A MX 2020005472A
Authority
MX
Mexico
Prior art keywords
maytansinoid
drug delivery
delivery systems
based drug
albumin
Prior art date
Application number
MX2020005472A
Other languages
English (en)
Inventor
Felix Kratz
Ajaj Khalid Abu
Stephan David Koester
Friederike I Nollmann
Fernandez Javier Garcia
Anna Warnecke
Lara Pes
Heidi-Kristin Walter
Johannes Pall Magnusson
Serghei Chercheja
Galan Patricia Perez
Federico Medda
Steffen Josef Daum
Original Assignee
Centurion Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centurion Biopharma Corp filed Critical Centurion Biopharma Corp
Publication of MX2020005472A publication Critical patent/MX2020005472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente materia proporciona profármacos de unión a albúmina, compuestos a base de maitansinoide y sus usos.
MX2020005472A 2017-11-30 2018-11-30 Sistemas de administración de fármacos a base de maitansinoide. MX2020005472A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593184P 2017-11-30 2017-11-30
PCT/US2018/063380 WO2019108975A1 (en) 2017-11-30 2018-11-30 Maytansinoid-based drug delivery systems

Publications (1)

Publication Number Publication Date
MX2020005472A true MX2020005472A (es) 2020-11-11

Family

ID=64744962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005472A MX2020005472A (es) 2017-11-30 2018-11-30 Sistemas de administración de fármacos a base de maitansinoide.

Country Status (11)

Country Link
US (2) US11572373B2 (es)
EP (1) EP3717018A1 (es)
JP (2) JP7442821B2 (es)
KR (1) KR20200117988A (es)
CN (1) CN111712263B (es)
AU (1) AU2018375788A1 (es)
BR (1) BR112020010989A2 (es)
CA (1) CA3083985A1 (es)
IL (2) IL274920B2 (es)
MX (1) MX2020005472A (es)
WO (1) WO2019108975A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748992C2 (ru) 2015-06-19 2021-06-02 Центурион Байофарма Корпорейшн Системы доставки для контролируемого высвобождения лекарственного средства
CN111712511B (zh) 2017-11-30 2024-07-16 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物
CN110227164B (zh) * 2018-03-06 2021-11-23 江苏吉贝尔药业股份有限公司 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用
WO2023114861A1 (en) 2021-12-15 2023-06-22 The Administrators Of The Tulane Educational Fund Conjugates, their compositions, and their related methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125704A (en) 1977-09-14 1978-11-14 Sri International Phenyl-substituted rubidazone analogs
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7238704B2 (en) 2003-12-04 2007-07-03 Amr Technology, Inc. Vinca derivatives
BRPI0811248A2 (pt) 2007-05-16 2014-11-04 Ktb Tumorforschungs Gmbh Formulação de antraciclina de baixa viscosidade.
EP2289558A1 (en) 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
WO2012145112A2 (en) * 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
ES2657014T3 (es) 2011-11-17 2018-03-01 Pfizer Inc. Péptidos citotóxicos y conjugados de fármaco anticuerpo de los mismos
EP2630971B8 (en) 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems
CN105849086B (zh) * 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
CN103333179B (zh) 2012-12-21 2017-06-16 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
US20140221429A1 (en) 2013-02-04 2014-08-07 Saud Ibrahim Al-Resayes Heterocyclic schiff's bases as novel and new antiglycation agents
EP2961434A2 (en) * 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CA2978340C (en) * 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
CA2987091A1 (en) 2015-06-15 2016-12-22 Abbott Diabetes Care Inc. Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same
RU2748992C2 (ru) * 2015-06-19 2021-06-02 Центурион Байофарма Корпорейшн Системы доставки для контролируемого высвобождения лекарственного средства
CN111712511B (zh) 2017-11-30 2024-07-16 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物

Also Published As

Publication number Publication date
CN111712263A (zh) 2020-09-25
US20230391794A1 (en) 2023-12-07
BR112020010989A2 (pt) 2020-11-17
CA3083985A1 (en) 2019-06-06
IL274920B2 (en) 2024-01-01
CN111712263B (zh) 2024-12-17
RU2020121456A (ru) 2021-12-30
IL305268A (en) 2023-10-01
KR20200117988A (ko) 2020-10-14
US20200385403A1 (en) 2020-12-10
IL274920A (en) 2020-07-30
IL274920B1 (en) 2023-09-01
JP2021505551A (ja) 2021-02-18
AU2018375788A1 (en) 2020-07-09
RU2020121456A3 (es) 2022-04-13
JP2023164604A (ja) 2023-11-10
US11572373B2 (en) 2023-02-07
WO2019108975A1 (en) 2019-06-06
JP7442821B2 (ja) 2024-03-05
EP3717018A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
GB201802837D0 (en) Awrosol delivery system
IL276784A (en) Drug delivery systems
EP3287400A4 (en) Delivery system
IL268773A (en) Systems for topical transfer of active compounds
EP3287399A4 (en) Delivery system
MX2020003760A (es) Formulaciones de niraparib.
MX2020004424A (es) Formulacion aerosolizable.
PH12016501841A1 (en) Immunosuppressant formulation
MX2019015167A (es) Farmacos antivirales.
MX2020005472A (es) Sistemas de administración de fármacos a base de maitansinoide.
GB201715590D0 (en) Delivery system
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
EP3452052A4 (en) AGENT ADMINISTRATION SYSTEM
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
EP3650484A4 (en) ACTIVE SUBSTANCE RELEASE CARRIERS DIRECTED TO THE KIDNEYS
IL275664A (en) drug delivery system
EP3217947A4 (en) Kidney-targeted drug delivery systems
HK40039292A (en) Maytansinoid-based drug delivery systems
HK40022899A (zh) 药物输送系统
AU2017904745A0 (en) Delivery System
MX2019003366A (es) Ajuste de la dosis.
HK40038909A (en) Ratchet systems for drug delivery devices
AU2018902755A0 (en) Directed Delivery System